Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CD38 | P28907 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871863 | 0.89 | EGFR (0.82) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL159209 | 0.85 | EGFR (1.00) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL29350058 | 0.85 | EGFR (1.00) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL4349199 | 0.85 | MAPK1 (1.00) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL13755817 | 0.84 | EGFR (0.74) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL11087835 | 0.84 | EGFR (0.80) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL8427296 | 0.84 | EGFR (0.74) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL9215676 | 0.84 | EGFR (0.74) | EGFRERBB2MAPK1HTTHIF1A | |
| Hydrochloric Acid SCHEMBL6186081 | 0.84 | MAPK1 (0.97) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL13755816 | 0.84 | EGFR (1.00) | EGFRERBB2MAPK1HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |